Novartis Ag (NVS) Other Non-Current Liabilities (2009 - 2026)
Novartis Ag recorded quarterly Other Non-Current Liabilities of -$100.0 million in Q1 2026, down 102.42% quarter-over-quarter from $4.1 billion in Q4 2025.
Novartis Ag's Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at -$100.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to -$100.0 million; the TTM figure through Mar 2026 stood at -$100.0 million (changed N/A YoY), while the FY2025 annual figure was $4.1 billion, up 1.42% from the prior year.
- Other Non-Current Liabilities came in at -$100.0 million for Q1 2026 at Novartis Ag, down from $4.1 billion in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $5.4 billion in Q2 2022 to a low of -$100.0 million in Q1 2026.
- A 5-year average of $3.2 billion and a median of $4.1 billion in 2025 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities decreased 14.93% in 2022 and surged 406.84% in 2024, its largest moves.
- Novartis Ag's Other Non-Current Liabilities stood at $874.0 million in 2022, then declined by 8.01% to $804.0 million in 2023, then soared by 406.84% to $4.1 billion in 2024, then advanced by 1.42% to $4.1 billion in 2025, then plunged by 102.42% to -$100.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered -$100.0 million, $4.1 billion, and $4.2 billion for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100.00 Mn |
| Dec 31, 2025 | 4.13 Bn |
| Jun 30, 2025 | 4.24 Bn |
| Dec 31, 2024 | 4.08 Bn |
| Jun 30, 2024 | 4.31 Bn |
| Dec 31, 2023 | 804.00 Mn |
| Jun 30, 2023 | 4.81 Bn |
| Dec 31, 2022 | 874.00 Mn |
| Jun 30, 2022 | 5.35 Bn |
| Dec 31, 2021 | 956.00 Mn |
| Jun 30, 2021 | 6.29 Bn |
| Dec 31, 2020 | 409.00 Mn |
| Jun 30, 2020 | 7.34 Bn |
| Dec 31, 2019 | 4.00 Mn |
| Jun 30, 2019 | 6.84 Bn |
| Dec 31, 2018 | 7.32 Bn |
| Sep 30, 2018 | 4.00 Mn |
| Jun 30, 2018 | 6.82 Bn |
| Dec 31, 2017 | 809.00 Mn |
| Sep 30, 2017 | -969.00 Mn |
| Jun 30, 2017 | -905.00 Mn |
| Mar 31, 2017 | -989.00 Mn |
| Dec 31, 2016 | 8.47 Bn |
| Sep 30, 2016 | -952.00 Mn |
| Jun 30, 2016 | -94.00 Bn |
| Mar 31, 2016 | -192.00 Bn |
| Dec 31, 2015 | -30.00 Mn |
| Sep 30, 2015 | -974.00 Bn |
| Jun 30, 2015 | 7.00 |
| Mar 31, 2015 | 18.00 |
| Dec 31, 2014 | -808.00 Bn |
| Sep 30, 2014 | 759.00 |
| Jun 30, 2014 | 757.00 |
| Mar 31, 2010 | 9,702.00 |
| Dec 31, 2009 | 9,898.00 |
| Sep 30, 2009 | 10,765.00 |
| Jun 30, 2009 | 9,232.00 |
| Mar 31, 2009 | 9,774.00 |